The trading price of Legend Biotech Corp ADR (NASDAQ:LEGN) closed higher on Friday, July 12, closing at $54.37, 12.10% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $77.32 and a 52-week low of $38.60. Over the past month, the stock has gained 22.87% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Legend Biotech Corp ADR, whose market valuation is $9.91 billion at the time of this writing. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest LEGN has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently Hold.
A quick review shows that LEGN’s price is currently 22.09% off the SMA20 and 23.23% off the SMA50. The RSI metric on the 14-day chart is currently showing 74.28, and weekly volatility stands at 6.79%. When measured over the past 30 days, the indicator reaches 5.05%. Legend Biotech Corp ADR (NASDAQ:LEGN)’s beta value is currently sitting at 0.12, while the Average True Range indicator is currently displaying 2.48.
To see how Legend Biotech Corp ADR stock has been performing in comparison to its peers in the industry, here are the numbers: LEGN stock’s performance was 12.10% in the latest trading, and -21.92% in the past year.
An evaluation of the daily trading volume of Legend Biotech Corp ADR (NASDAQ:LEGN) indicates that the 3-month average is 1.13 million.
Currently, records show that 181.91 million of the company’s shares remain outstanding. The insiders hold 0.83% of outstanding shares, whereas institutions hold 47.03%. However, since the stock’s price has seen -9.64% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.
